Exclusive Summary

• Targets over 537 million diabetic patients globally, especially high-carb diet populations, highly effective in controlling postprandial hyperglycemia and Impaired Glucose Tolerance (IGT).
• Chewable tablet and capsule formulations offer a distinct competitive edge by enabling water-free consumption, significantly improving treatment adherence for the elderly and dysphagia patients.
• Exhibits higher enzyme selectivity and remarkably fewer gastrointestinal side effects compared to Acarbose, well-recommended in various international diabetes clinical guidelines.
• Completely off-patent with zero IP barriers, leveraging China's integrated API-FDF supply chain to provide highly competitive costs and lucrative margins for overseas distributors.